Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 8/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.46 |
| ▸ | SORD | Q00796 | 1/20 | 0.45 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29241190 | 1.00 | GRM1 (0.47) | GRM1TRPV1SORDSLC6A7MAP4K4 | |
| SCHEMBL15022525 | 0.85 | TRPV1 (0.46) | TRPV1SORDSLC6A7 | |
| SCHEMBL29241306 | 0.84 | MAP4K4 (0.61) | GRM1TRPV1SORDMAP4K4 | |
| SCHEMBL24338375 | 0.84 | MAP4K4 (0.61) | GRM1TRPV1SORDMAP4K4 | |
| SCHEMBL4573042 | 0.78 | SLC6A7 (0.45) | GRM1SLC6A7 | |
| SCHEMBL12100509 | 0.77 | GRM1 (0.70) | GRM1SLC6A7 | |
| SCHEMBL23860175 | 0.77 | GRM1 (0.47) | GRM1SLC6A7 | |
| SCHEMBL20798392 | 0.77 | PIK3CD (0.39) | GRM1SLC6A7 | |
| SCHEMBL20798393 | 0.77 | PIK3CD (0.39) | GRM1SLC6A7 | |
| SCHEMBL4815499 | 0.76 | TRPV1 (0.64) | TRPV1SORD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515956-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240132483-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2024-04-25 | — | — | US | disclosed |
| US-11858916-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3806855-B1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2023-03-01 | — | — | EP | disclosed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| US-20210332034-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3806855-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858916-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GRM1 257/4885TRPV1 709/4885SORD 4687/4885 |
| US-20240132483-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GRM1 257/4885TRPV1 709/4885SORD 4687/4885 |
| US-20210332034-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GRM1 257/4885TRPV1 709/4885SORD 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.